The 2026 edition of Eco Deals offers accommodation partners enhanced visibility while continuing to support the protection of wildlife and conservation of critical habitats in Asia

SINGAPORE, Jan. 27, 2026 /PRNewswire/ — Digital travel platform Agoda and the World Wide Fund for Nature (WWF) launch the fifth edition of Eco Deals, marking five years of impactful partnership and conservation achievements across Asia. The 2026 program will continue its highest funding commitment to-date of US$1.5 million to support conservation efforts in 10 markets across Asia. This year’s launch also marks the signing of a new five-year Memorandum of Understanding (MoU), strengthening the ongoing partnership between Agoda and WWF to advance conservation efforts, raise traveler awareness, and drive industry engagement for sustainable tourism throughout Asia.

Launching on 19 January, the 2026 Eco Deals program will begin with a month-long campaign offering travelers discounts of up to 20% at participating properties to mark the program’s fifth anniversary. The program will then continue with a year-round offering, providing savings of up to 15% for travelers until 18 December. Throughout the campaign, travelers can easily identify participating accommodations through dedicated program pages and on‑site identification features across Agoda’s platforms.  As in previous editions, Agoda will donate US$1 towards WWF`s conservation efforts for every completed program booking made at a participating hotel.

Eco Deals enables accommodation partners to support conservation efforts across Asian destinations, helping protect the natural environments and biodiversity that are essential to the region. In 2025, the program continued to scale across the region, growing to nearly 10,000 participating properties. Since it was first launched in 2022, Eco Deals has raised US$2.89 million for conservation projects, supporting efforts such as protecting the Malayan tiger in Malaysia, safeguarding Asian elephants in Thailand, and conserving whale sharks in the Philippines. These efforts contribute to broader regional progress towards the Kunming-Montreal Global Biodiversity Framework ’30×30′ goal, which aims to bring 30% of the world’s land and oceans under effective protection by 2030.

Participating partners will receive the Eco Deals badge, signaling their support to the protection of wildlife and nature across Asia. Partners will also benefit from marketing support across Agoda platforms, including targeted marketing placements such as banner promotions, customer communications, social media features and in-app discovery. Eco Deals properties will also be featured on dedicated program pages across Agoda’s desktop and mobile platforms, helping travelers discover and support accommodations whose bookings contribute to conservation efforts. Upon its conclusion, participating properties will receive a certificate recognizing their involvement in the program.

“Eco Deals reflects five years of collaboration with WWF to support conservation efforts to protect Asia’s most remarkable destinations, alongside a growing network of accommodation partners,” said Andrew Smith, Senior Vice President, Supply, Agoda. “The signing of a new five-year MoU with WWF is a testament to our shared vision and action for long-term conservation and industry collaboration. In the past year alone, the program has seen participating properties grow by more than 45%, with strong momentum in markets like Indonesia, the Philippines and Malaysia. But what’s most rewarding is seeing how Eco Deals has become a platform for hotels to differentiate themselves, connect with sustainability‑minded travelers and contribute to meaningful conservation work across Asia.”

“Nature is a source of wonder and a vital lifeline for communities and wildlife,” said Hsieh Fu Hua, Chairman, WWF-Singapore. “Eco Deals shows how the tourism industry can actively contribute to nature-positive outcomes while creating value for travelers and destinations alike. By working across markets and a broad network of stakeholders, this partnership helps link local conservation priorities with regional coordination to protect nature today and for future generations.”

With a global network of accommodations and travel offerings, Agoda remains committed to working with partners to support responsible travel and conservation initiatives across the region. Together with WWF, Agoda invites hotel partners to take part in this year’s Eco Deals program and contribute towards conservation initiatives across Asia. For more information, visit www.agoda.com/ecodeals.

BEIJING, Jan. 27, 2026 /PRNewswire/ — Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for viral hepatitis and the first approved treatment for HDV in China, addressing a major clinical gap in this field. The drug previously received “Breakthrough Therapy Designation” from both the Center for Drug Evaluation (CDE) of the China NMPA and the U.S. Food and Drug Administration (FDA).

Guidelines from the World Health Organization (WHO) and the European Association for the Study of the Liver (EASL) consistently identify HDV–HBV co-infection as the most severe form of chronic viral hepatitis due to rapid progression towards liver cirrhosis, hepatocellular carcinoma and liver-related death ^{[1] [2]}. HDV is a satellite virus that depends on HBV’s envelope proteins to complete its life cycle and therefore infects only individuals who are co-infected with HBV. Chronic HDV–HBV co-infection leads to a higher risk of cirrhosis and liver cancer compared to HBV mono-infection, accounting for approximately one in six cases of cirrhosis and one in five cases of liver cancer among people with HBV infection globally ^[3].

According to WHO, HDV affects nearly 5% (an estimated 12 million) of people who have a chronic infection with HBV. Given the severe consequences of HDV infection, WHO’s 2024 Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection recommend that serological testing for anti-HDV antibodies may be performed for all individuals who are HBsAg positive, as the preferred approach to scale up access to HDV diagnosis and linkage to care. In China, with over 75 million patients living with chronic hepatitis B, limited HDV therapies, compounded by inadequate clinical awareness and low testing rates, have left patients with no treatment options, underscoring a pressing unmet medical need.

Clinical development of Libevitug began in 2018. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter, randomized, controlled, open-label Phase IIb clinical trial demonstrated that Libevitug was significantly superior to the control group across primary and secondary efficacy endpoints including combined response rate, virological response, alanine aminotransferase (ALT) normalization, and improvement in liver stiffness. Libevitug also showed favorable tolerability and a satisfactory safety profile. At Week 48, the combined response rate reached 44.1%, along with an HDV virological response rate of 60% and an ALT normalization rate of 70%, and a significant, sustained improvement in liver stiffness.

“Libevitug demonstrates outstanding clinical efficacy and significantly improves liver stiffness, with particularly remarkable efficacy in patients with HBV/HDV-related cirrhosis,” stated Professor Niu Junqi, principal investigator of the Libevitug (HH003-204) trial from the First Hospital of Jilin University. “This drug aligns with the core objectives of China’s Action Plan for the Prevention and Control of Viral Hepatitis (2025–2030), which aims to improve diagnosis and treatment rates for viral hepatitis and reduce the incidence of liver cancer and mortality. We anticipate that Libevitug will help effectively lower the risk of disease progression to advanced severe diseases such as liver cancer, drive the standardization of HDV diagnosis and treatment in China, advance the goal of eliminating viral hepatitis as a public health problem by 2030, and contribute a scientifically robust and accessible solution from China to global hepatitis control efforts.”

The development of Libevitug stems from a scientific breakthrough over a decade in the making. In 2012, a team at the National Institute of Biological Sciences, Beijing (NIBS) led by Dr. Li Wenhui, scientific founder of Huahui Health, identified the sodium taurocholate cotransporting polypeptide (NTCP) as the critical receptor for HBV and HDV infections—a world-first discovery solving a decades-long scientific mystery. This landmark achievement earned Dr. Li prestigious accolades, including the Baruch S. Blumberg Prize, the Future Science Prize, and the Distinguished Award in Hepatitis B Research, and opened a door for new drug development. In 2015, the lead molecule of Libevitug was developed through a collaboration between Dr. Sui Jianhua, co-founder of Huahui Health and an antibody engineering expert, and Dr. Li’s team. “The global burden of viral hepatitis is immense,” stated Dr. Sui. “We are pleased that Libevitug is the first monoclonal antibody approved in this field, effectively treating the most severe and progressive form of chronic viral hepatitis—HDV co-infection with HBV.” Dr. Li added, “We are grateful for the invaluable support from all our partners and collaborators. The teams at Huahui Health and NIBS have worked together to complete the full-cycle of biomedical innovation from ‘uncovering fundamental mechanism’ to ‘developing effective drugs’, positioning us at the leading edge of this field and demonstrating our capability and commitment to tackling critical challenges in human health.”

Dr. Chen Bin, Chief Executive Officer of Huahui Health, stated, “The successful approval of Libevitug fulfills our commitment to building a world-class translational and clinical development platform dedicated to delivering innovative therapies for patients worldwide. We have established an integrated R&D system covering the entire drug development process, with a pipeline expanding from HDV and HBV to oncology and other liver diseases, comprising eight core asset candidates. Going forward, we remain steadfastly committed to our vision of ‘Original in China, Benefiting the Globe’, leveraging science to safeguard global healthcare in infectious and liver diseases.”

References:

[1] World Health Organization. Hepatitis D Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d
[2] European Association for the Study of the Liver. J Hepatol. 2023 Aug; 79(2)433-460.
[3] WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024.

About Chronic HDV Infection

HDV is a satellite virus of HBV, relying on HBV’s envelope proteins to complete its life cycle. HDV infects hepatocytes by binding to NTCP, a receptor shared with HBV. HDV infection occurs only in individuals with concurrent HBV infection. Compared to HBV mono-infection, co-infection with HBV and HDV significantly increases—often doubling—the risk of developing liver cirrhosis, hepatocellular carcinoma (HCC), requiring liver transplantation, and liver-related mortality, making it the most severe known form of chronic viral hepatitis. According to the WHO, approximately 12 million people worldwide are infected with HDV, affecting nearly 5% of all chronic HBV carriers. WHO recommends screening and testing for hepatitis D in all hepatitis B surface antigen (HBsAg)-positive individuals. Until now, aside from Europe, no drugs for chronic HDV infection had been approved in China or the United States.

About Libevitug (HH-003)

Libevitug is a first-in-class, PreS1-targeting neutralizing monoclonal antibody against HBV/HDV, discovered and developed by Huahui Health. The antibody functions by specifically blocking the interaction between the viral PreS1 domain and the host NTCP receptor, preventing viral entry into hepatocytes and reinfection. The early-stage development of Libevitug received support from the National Major Science and Technology Project for Significant New Drugs Development under China’s 13th Five-Year Plan. Previously, it was granted Breakthrough Therapy Designation (BTD) for Hepatitis D by both China’s CDE, NMPA (2023) and the U.S. FDA (2024).

About Huahui Health

Founded in Beijing in 2015, Huahui Health is a biopharmaceutical company dedicated to developing first-in-class and best-in-class therapies, with a strategic focus on viral hepatitis, liver diseases, and oncology. Driven by a patient-centric philosophy and profound scientific expertise, Huahui Health operates under the core principles of Innovation, Integrity, Collaboration, and Mutual Benefit. Huahui Health has built integrated, world-class proprietary platforms that cover the entire new drug development process, ensuring sustained delivery of breakthrough therapies for patients worldwide.

For more information, please visit www.huahuihealth.com.

BEIJING, Jan. 27, 2026 /PRNewswire/ — Huahui Health announced that China’s National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus (HBV) and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China’s first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clinical gap.

According to the World Health Organization (WHO), HDV affects nearly 5% (an estimated 12 million) of people with chronic HBV infection. HDV–HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death. 

Libevitug was previously granted “Breakthrough Therapy Designation” by China’s NMPA and the U.S. FDA. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker Abstract at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter, randomized, controlled, open-label Phase IIb clinical trial demonstrated that Libevitug was significantly superior to the control group across primary and secondary efficacy endpoints including combined response, virological response, alanine aminotransferase (ALT) normalization rate, and improvement in liver stiffness. The drug also showed favorable tolerability and a satisfactory safety profile. At Week 48, the combined response rate reached 44.1%, along with an HDV RNA virological response rate of 60% and an ALT normalization rate of 70%, and a significant, sustained improvement in liver stiffness. Libevitug is poised to provide a novel and accessible treatment option for hepatitis D patients worldwide.

Huahui Health is dedicated to developing first-in-class and best-in-class therapies, with a strategic focus on viral hepatitis, liver diseases, and oncology. It has established an integrated R&D system covering the entire drug development process, enabling it to continuously deliver breakthrough therapies for patients across the globe.

About Huahui Health

Huahui Health is a biopharmaceutical company headquartered in Beijing, dedicated to innovating breakthrough therapies in virology, hepatology and oncology through its proprietary, world-class drug development platforms.

For more information, please visit www.huahuihealth.com.

• Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24.
• Growth over the financial year was driven by increased sales in oncology, particularly in the United States.
• Several partnership agreements in oncology and neurology strengthen the Group’s R&D portfolio in rare diseases.
• Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group’s ambitions for 2030.

SURESNES, France, Jan. 27, 2026 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, published its financial results for the 2024/25 financial year today and recapped the highlights that led to such significant growth.

Olivier Laureau, President of Servier, said: “The solid results from our 2024/25 financial year put us one important step closer to achieving our 2030 objectives. They validate the relevance of our differentiated innovation strategy to serve patients and the commitment of our employees. These results also underscore the success of the Group’s transformation, which began 10 years ago, involving significant investments in innovation and international expansion. Our long-term vision is made possible by the fact that we are governed by a foundation.”

Excerpt from the Group’s audited results^[1] (financial year ending September 30, 2025)

In the 2024/25 financial year, Group revenue reached €6.9 billion, exceeding the €6 billion target. This 16.2% increase over the previous year reflects the Group’s growth momentum and ability to provide patients with an ever-increasing number of medicines.

Revenue growth resulted from a 16.9% increase in sales volume, or €1 billion, compared to 12.6% for FY 2023/24. There was also an unfavorable currency effect of 2.0%, equivalent to €118 million, (compared with an unfavorable impact of 3.5% in the previous year), as well as a positive price effect of 1.3%, equal to €76 million (compared with 1.7% for the 2023/24 financial year).

EBITDA^[2] for the 2024/25 financial year amounted to €1.9 billion, corresponding to a 28.2% revenue margin compared to 22.2% in 2023/24. This increase was driven by significant growth in medicine sales during the financial year, particularly in oncology, combined with effective cost control across the Group. By 2023/24, the Group had already exceeded its 2024/25 target of achieving a 21.7% EBITDA margin.

Consistent with strategy, Servier remains confident in its ability to achieve global annual revenues of €10 billion by 2030 and an EBITDA margin of at least 30%.

Growth fueled by oncology performance in the United States

The 2024/25 financial year was highlighted by several advances in oncology and partnership agreements signed, reflecting the Group’s dedication to developing new therapeutic solutions for patients with rare cancers. In line with the Group’s strategy, oncology continues to grow and now accounts for 32.2% of Group revenue, compared with 24.2% in 2023/24. Oncology revenues amounted to €2.21 billion in 2024-25, an increase of 54.6%. This growth stems from a significant increase in oncology sales volume following the launch of Voranigo® in the United States.

Medicine sales in cardiometabolism and venous diseases underscore the Group’s historic, ongoing commitment in this area. As a result, sales rose by 1.8% to €2.968 billion, boosted by strong sales performance for Daflon^® in venous diseases.

European Union revenues account for 40.5% of Group revenue and show a 9.2% increase over the previous financial year. The US subsidiary remained the Group’s leading operating unit, with revenues of €1.496 billion in 2024/25, compared with €879 million in 2023/24, reflecting growth of 70.3%. The US market generated 21.8% of Group revenue.

Pascal Lemaire, Executive Vice President Finance at Servier, said: “The Group’s 2024/25 financial year results mirror our successful international growth, particularly our oncology business in the United States. They reward the risks taken as part of our targeted strategy and our policy of investing in R&D in rare diseases in oncology and in neurology where there are unmet patient needs. Our results are also a testament to Servier’s decision to raise its growth targets for 2030, particularly to reach €10 billion in revenue.”

Targeted, collaborative R&D to enhance and strengthen the pipeline

In 2024/25, the innovation strategy focused on renewing and sustaining our research and development pipeline through both internal and external growth.

Incorporating AI (artificial intelligence) and data throughout the medicine development chain has now become part of Servier’s ambition to improve R&D productivity to serve patients. AI helps researchers navigate biological complexity and speed up the development of treatments for the right patient at the right time, particularly in rare diseases in oncology and neurology.

Targeted innovation driving growth in oncology

The 2024/25 financial year was once again noteworthy for several marketing authorizations in oncology around the world, bolstering the Group’s ability to develop new therapeutic solutions for rare forms of cancer with unmet medical needs, and get them to patients.

Following approvals in the United States, Australia, Japan, and Brazil, Voranigo^® has now been approved in Europe, bringing the total number of countries to nearly 45. Used to treat patients with a rare form of brain cancer, Voranigo^® is currently administered to more than 5,500 patients in the United States and around the world through early access programs. Alongside this, Tibsovo^®, a targeted therapy in hematology, has been approved for marketing in Japan.

In addition, the Group has finalized three significant partnership agreements that demonstrate its focus on advancing targeted oncology therapies and the value creation potential of its R&D. The Group entered into a licensing agreement with Black Diamond Therapeutics to develop and commercialize a targeted therapy for solid tumors, including non-small cell lung cancer. Additionally, the acquisition of a precision therapy from Chinese biopharmaceutical company BioNova Pharmaceuticals Ltd also enabled the Group build on its leadership in acute leukemia. And finally, Servier joined forces with IDEAYA Biosciences to make Darovasertib available to patients. This is a potential treatment for uveal melanoma, which is a rare type of eye cancer.

Featuring in the Top 10 of the PatientView Survey^[3] and obtaining the leading position in the oncology category are recognition of the Group’s unwavering dedication to patients and patient advocacy groups.

Aspiring to be a leading force in neurology

Building on its ongoing transformation, the Group aims to establish a leading neurology franchise by developing a robust pipeline in rare neurological diseases modeled on its oncology strategy. Servier is targeting three main types of neurological diseases associated with a genetic and/or immuno-inflammatory mechanism: refractory epilepsy, rare movement disorders, and neuromuscular diseases. Servier R&D is focused on small molecules that target messenger RNA, particularly antisense oligonucleotides (ASOs), as well as pharmacological molecules and monoclonal antibodies. To date, the neurology pipeline comprises eight research projects and three projects in development.

Servier has initiated a Phase 1 clinical trial for a product to treat developmental and epileptic encephalopathy (DEE) in children, a rare form of epilepsy that is resistant to conventional anticonvulsant drugs. In the field of DEE, the Group has also partnered with University College London to test ASOs from Servier in innovative cell models, called brain assembloids, which replicate key aspects of human brain development and function.

Leveraging the strength of its global resources, Servier also intends to become a partner of choice for innovative biotech companies in the development of new drugs that slow or halt the progression of rare neurological disorders and significantly improve patient quality of life.

Over the past year, the Group has therefore enriched its pipeline with the acquisition of a first asset in autism spectrum disorder (ASD) from biotech company Kaerus Bioscience Ltd. This asset is a potential treatment for Fragile X syndrome, the most common genetic cause of ASD, for which there are currently no treatment options.

Innovation continues with a focus on improving patient adherence to cardio-metabolic therapies

Servier maintains its position as the world’s leading pharmaceutical company in hypertension[4]. Cardiometabolism and venous diseases accounted for 43.3% of consolidated revenues in FY 2024/25, with performance driven by sales of Daflon^® as well as growth in Single Pill Combinations (SPCs), which make it possible for patients with multiple and chronic conditions to take their various treatments in a single pill.

Several marketing authorization applications were submitted in many countries for an extended-release triple therapy in hypertension and its first quadruple therapy. These innovations are designed to address the issue of treatment non-adherence, a major health challenge for the nearly 50% of patients with chronic diseases who do not follow their prescribed treatment plans exactly[5], which also places a financial burden on health care systems. Among other initiatives, Servier partnered with 14 institutions to sponsor the first World Adherence Day.

Claude Bertrand, Executive Vice President Research and Development at Servier: “Our differentiated approach is paying off. Following major oncology launches in 2025 that consolidate our expertise in rare cancers, we are investing in rare neurological diseases while continuing our innovations in Single Pill Combinations (SPCs) in cardiometabolism. All our R&D projects are clinically grounded and focused on critical unmet medical needs, leveraging recent scientific and technological inflection points. They represent decisive and sustainable choices with one ultimate beneficiary: the patient.”

Last but not least, the creation of Servier’s venture capital fund — Servier Ventures — will also help further the Group’s R&D strategy by strengthening direct, early access to innovation in its target therapeutic areas and fueling the long-term pipeline. Through investment and support for innovative start-ups, this fund gives Servier the opportunity to position itself as a partner of choice within the biotech ecosystem, promoting the development of new and innovative medicines.

Press Contact
presse@servier.com 

About Servier 

Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.

As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D.

Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.

More information on the Group website: servier.com 

Follow us on social media: LinkedIn, Facebook, X, Instagram 

[1] The Group’s 2024/25 financial information is presented on a pro forma basis, comparable to the previous financial year, and includes Biogaran business. Excluded are restatements related to IFRS 5 regarding businesses held for sale.

[2] EBITDA is used as an indicator of operating performance (EBITDA: Earnings before interest, taxes, depreciation, and amortization) based on recurring operating income excluding items such as asset disposals and other non-recurring costs.

[3] PatientView’s Corporate Reputation of Pharma, 2024. The Patient Perspective — Global Edition.

[4]  IQVIA, Analytics Link / World 84 countries – MAT Q3-2025

[5] Adherence to Long-Term Therapies: Evidence for action. World Health Organization, 2003.

 

HONG KONG, Jan. 27, 2026 /PRNewswire/ — Hong Kong’s first CSI A500 Index ETF— CSOP Huatai-PineBridge CSI A500 ETF (Stock Code: 3101.HK), will list on Hong Kong Stock Exchange (HKEX) on January 28, 2026. The listing price for 3101.HK is approximately HKD 7.9 per share, the trading lot size is 100 shares, and the annual management fee is 0.99%.

The listing of CSOP Huatai-PineBridge CSI A500 ETF on HKEX marks the continued opening-up of China’s financial markets and an important step in the internationalization of Chinese assets. 3101.HK is a feeder fund that, to achieve its investment objective, will invest at least 90% of its NAV in the Huatai-PineBridge CSI A500 ETF (the master fund) via the QFI status granted to CSOP Asset Management and/or the Shanghai-Hong Kong Stock Connect. The master fund was listed on Shanghai Stock Exchange in 2024 and, as of January 8, 2026, has approximately RMB 49.5 billion in assets under management, the largest among peer products globally^[1]. The fund features low tracking error, high index replication, and significant scale advantages. Hong Kong investors can trade this ETF on the secondary market in HKD, with a minimum investment of about HKD 790, to capture the long-term growth opportunities of China’s core assets.

The CSI A500 Index (the Index) selects 500 A-share securities with relatively large market capitalization and strong liquidity from across industries as its constituents, aiming to reflect the overall performance of the most representative listed companies in each sector. From an industry allocation perspective, the CSI A500 Index has higher weights in Industrials, Information Technology, Materials, Financials, and Communication Services, which may enhance its potential to deliver relative excess returns. In 2025, CSI A500 Index achieved a return of 22.43%^[2].

Mr. Zhou Yi, CEO of Huatai Securities and Chairman of China Southern Asset Management Co., Ltd. (CSAM) and CSOP Asset Management Limited (CSOP), said: “The listing of CSOP Huatai-PineBridge CSI A500 ETF in Hong Kong is an important step in CSOP’s comprehensive ETF strategy. Leveraging our collaboration with Huatai-PineBridge Investments, this product provides Hong Kong investors with a new channel to invest in leading companies across China’s mainstream industries, helps enrich Hong Kong’s ETF market, and meets investors’ demand for allocating to broad-based A-share indices.”

About CSOP

For over a decade, CSOP has successfully established itself as one of the leading ETF issuers in Hong Kong, with the second largest AUM and demonstrated innovative product development. As of 31 December 2025, the total AUM of CSOP reached 27.4 billion USD by building a healthy ETF ecosystem and managing 64 ETPs and 4 mutual funds in Hong Kong and Singapore markets*. In 2025, 6 out of the top 10 most actively traded ETPs in Hong Kong are managed by CSOP**.

*Source: CSOP
** Source: Bloomberg, from 1 January 2025 to 31 December 2025

Disclaimer and Important Notices

Investment involves risks. Investors should refer to the Prospectus and the Product Key Facts Statement for further details, including product features and the full list of risk factors. This material is prepared by CSOP Asset Management Limited and has not been reviewed by the Securities and Futures Commission in Hong Kong. Please read the detailed disclosure and disclaimer carefully by accessing website (https://www.csopasset.com/en/education/disclaimer_en.html).
Issuer: CSOP Asset Management Limited

[1] Source: Shanghai Stock Exchange
[2] Source: China Securities Index Co., Ltd.